KaloBios Pharma (KBIO) Tops Q2 EPS by 22c

KaloBios Pharma (NASDAQ: KBIO) reported Q2 EPS of ($1.46), $0.22 better than the analyst estimate of ($1.68).

For earnings history and earnings-related data on KaloBios Pharma (KBIO) click here.

You May Also Be Interested In

• Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
• Hawaiian Electric trades at 8.8x P/E, but wildfire risk clouds value case
• Why JPM thinks rising bond yields won’t derail the equity rally